Search | IOVS | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 14 of 14

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

The Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study - 2 Year Results

Aamir Abdul Aziz; Hannah Khan; Mark Rami Barakat; Ramanath Bhandari; Emmanuel Chang; Giulia Corradetti; Carl J Danzig; Jordan M Graff; Nikolas JS London; Jared Nielsen; Veeral Sheth; Jeremy Wolfe; Robert William Wong; SriniVas R Sadda; Michael Andrew Singer; Arshad M. Khanani

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2789.

ARVO Annual Meeting Abstract June 2024

The 18-Month Efficacy of Avacincaptad Pegol in Geographic Atrophy: Pooled Results from GATHER1 and GATHER2

Greggory Gahn; Peter K Kaiser; Arshad M. Khanani; Carl J Danzig; Jeffrey S Heier; Julie Clark; Liansheng Zhu; Hersh Patel; Don Luo; Nikhil Patel; Glenn J Jaffe

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4400.

ARVO Annual Meeting Abstract June 2024

Visual and Anatomic Outcomes in nAMD Patients with Subretinal Hemorrhage After Treatment with Faricimab in the TRUCKEE Study

Ohidul Mojumder; Aamir Abdul Aziz; Hannah Khan; Ashkan Michael Abbey; Robert L Avery; Himanshu K Banda; Mark Rami Barakat; Ramanath Bhandari; Emmanuel Chang; Sara Haug; Nikolas London; Veeral Sheth; Jeremy Wolfe; Michael Andrew Singer; Carl J Danzig; Arshad M. Khanani

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):5675.

ARVO Annual Meeting Abstract June 2024

Screen failures in clinical trials in retina

Nasiq Hasan; Kunaal Mehrotra; Carl J Danzig; David Aaron Eichenbaum; Amy Ewald; Carl Regillo; Bita Momenaei; Veeral Sheth; David Ryan Lally; Jay Chhablani

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):5104.

ARVO Annual Meeting Abstract June 2024

The Real-World Efficacy and Safety of Faricimab in Diabetic Macular Edema: The TAHOE Study

Huma Khan; Hannah Khan; Aamir A Aziz; Greggory Gahn; Mark Rami Barakat; Giulia Corradetti; Carl J Danzig; Jordan M Graff; Jared Nielsen; Jeremy Wolfe; SriniVas R Sadda; Arshad M. Khanani

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6259.

ARVO Annual Meeting Abstract June 2023

The Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study

Aamir Abdul Aziz; Hannah Khan; Ashkan Michael Abbey; David RP Almeida; Robert L Avery; Himanshu K Banda; Mark Barakat; Ramanath Bhandari; Emmanuel Y Chang; Sara Haug; Nikolas J S London; Veeral Sheth; Jeremy Wolfe; Michael Andrew Singer; Carl J Danzig; Arshad M. Khanani

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2190.

ARVO Annual Meeting Abstract June 2023

Visual and Anatomic Outcomes in nAMD Patients with Subretinal Hemorrhage After Treatment with Faricimab in the TRUCKEE Study

Hannah Khan; Aamir Abdul Aziz; Ashkan Michael Abbey; David RP Almeida; Robert L Avery; Himanshu K Banda; Mark Barakat; Ramanath Bhandari; Emmanuel Y Chang; Sara Haug; Nikolas J S London; Veeral Sheth; Jeremy Wolfe; Michael Andrew Singer; Carl J Danzig; Arshad M. Khanani

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2187.

ARVO Annual Meeting Abstract June 2023

Treatment response to avacincaptad pegol by baseline patient characteristics: A prespecified subgroup analysis of the phase 3 GATHER2 study

Carl J Danzig; Peter Kaiser; David Lally; Glenn J Jaffe; Arshad M. Khanani; Charles Clifton Wykoff; Jeffrey S Heier; Justin Tang; Liansheng Zhu; Julie Clark

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):984.

ARVO Annual Meeting Abstract June 2022

Patient characteristics from a post hoc analysis of nascent geographic atrophy progression following treatment with avacincaptad pegol from the GATHER1 study

Carl J Danzig

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1502.

ARVO Annual Meeting Abstract June 2022

Efficacy, durability, and safety of faricimab in diabetic macular edema: 2-year results from the phase 3 YOSEMITE and RHINE trials

Jennifer I Lim; John A Wells; David Aaron Eichenbaum; Carl J Danzig; Kemal Asik; Zdenka Haskova; Shaun Mohan; David Silverman; Yannan Tang; Hugh Lin

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3850.

ARVO Annual Meeting Abstract June 2021

Real World Efficacy and Safety of Brolucizumab in Neovascular AMD: The REBEL Study

Aamir Abdul Aziz; Arshad M. Khanani; Nikolas London; Molly M. Hagen; Carl J Danzig; Amol D Kulkarni; Veeral S Sheth; Chirag D Jhaveri; David Aaron Eichenbaum; Michael Singer

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):451.

ARVO Annual Meeting Abstract June 2021

Phase 1 Study of Intravitreal Gene Therapy with ADVM-022 for neovascular AMD (OPTIC Trial)

Brandon Busbee; David S Boyer; Arshad M. Khanani; Charles Clifton Wykoff; Dante Joseph Pieramici; Carl Regillo; Carl J Danzig; Brian C Joondeph; James Major; Carol Hoang; Adam Turpcu; Carol Chung; Szilard Kiss; Mehdi Gasmi; Aaron Osborne

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):352.

ARVO Annual Meeting Abstract June 2021

Clinical trial versus real-world outcomes with anti-VEGF therapy for branch and central retinal vein occlusion

Carl J Danzig; Steven Blotner; Verena Steffen; Zdenka Haskova

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3174.

ARVO Annual Meeting Abstract June 2020

Clinical Effects of Blocking Ang-2 and VEGF with Faricimab in the Phase 2 STAIRWAY Trial

Carl J Danzig; Hugh Lin; Pascal Guibord; David Silverman; Carlos Quezada Ruiz; Ivo Stoilov; Zdenka Haskova

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1160.

Advertisement